Richardson, P G
Hofmeister, C C
Raje, N S
Siegel, D S
Lonial, S
Laubach, J
Efebera, Y A
Vesole, D H
Nooka, A K
Rosenblatt, J
Doss, D
Zaki, M H
Bensmaine, A
Herring, J
Li, Y
Watkins, L
Chen, M S
Anderson, K C
Article History
Received: 7 April 2017
Accepted: 1 May 2017
First Online: 2 June 2017
Change Date: 14 September 2018
Change Type: Correction
Change Details: Following the publication of this article the authors noted that the pomalidomide dose for the additional SC cohort in Figure 1 was incorrectly listed. The correct dose for pomalidomide in the additional SC cohort should be the maximum tolerated dose of 4 mg/day, not 2 mg/day as listed in the original figure 1. The authors apologize for any inconvenience caused.
Competing interests
: PGR has served on advisory committees for Celgene, Novartis, Millennium and Takeda. CCH, YAE and JR have nothing to disclose. NSR has served as a consultant for Celgene, Takeda, Bristol-Myers Squibb, Amgen, Onyx, Millennium and Novartis and has received research funding from AstraZeneca, Eli Lilly and Acetylon. DSS has served on speakers bureaus for Celgene, Amgen, Takeda, Novartis and Merck. SL has served as a consultant for and received research funding from Celgene, Millennium, Novartis, Bristol-Myers Squibb, Onyx and Janssen. JL has received research funding from Celgene, Onyx, Millennium and Novartis. DHV has served on speakers bureaus for Celgene and has received research funding from Idera Pharmaceuticals. AKN has served as a consultant for Onyx and Spectrum Pharmaceuticals. DD has served on speakers bureaus for Celgene and Takeda. MHZ, YL and MSC are employees of and hold equity ownership in Celgene. AB, JH and LW are employees of Celgene. KCA has served as a consultant for Celgene, Millennium, Bristol-Myers Squibb and Gilead and has equity ownership in Acetylon and Oncocorp.